Short-term effect analysis of radiofrequency ablation combined chemotherapy on middle and late period non-small cell lung cancer

Yu,Shuo; Wu,Zhen Zhou; Si,Hong Tao; Yang,Sai; Liu,Guang Mao; Zhao,Xiao Dong

doi:10.3892/ol.2016.5276

Short-term effect analysis of radiofrequency ablation combined chemotherapy on middle and late period non-small cell lung cancer

Authors:
- Shuo Yu
- Zhen Zhou Wu
- Hong Tao Si
- Sai Yang
- Guang Mao Liu
- Xiao Dong Zhao
View Affiliations

Affiliations: Department of Oncological Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: October 18, 2016 https://doi.org/10.3892/ol.2016.5276
Pages: 4399-4402
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this study, we investigated the effect of radiofrequency ablation (RFA) combined chemotherapy on middle and late period non-small cell lung cancer (NSCLC). In total, 85 cases of middle and late period NSCLC patients were selected, and were randomly divided into the RFA combined chemotherapy group, RFA treatment group and chemotherapy group. After treatment, the three groups were followed up for computed tomography (CT) scan, and were analyzed for the effect of RFA combined chemotherapy on middle and late period NSCLC. It was found that CT value of RFA combined chemotherapy group decreased significantly compared to before surgery (P<0.05). The CT value of the RFA group decreased significantly compared to before surgery (P<0.05). The CT value of chemotherapy group was not significantly changed compared to before surgery (P>0.05). The postoperative CT value of the RFA combined chemotherapy group and RFA group was smaller compared to that of the chemotherapy group (P<0.05). Effective rate [complete response (CR) + partial response (PR)] of RFA combined chemotherapy group was significantly higher than that of the EFA and chemotherapy groups (P<0.05). Effective rate (CR+PR) of the RFA group was significantly higher than that of the chemotherapy group (P<0.05). By contrast, the progressive rate (P) of RFA combined chemotherapy group was significantly lower than that of the RFA and chemotherapy groups (P<0.05). In conclusion, RFA combined chemotherapy has obvious effect on middle and late period NSCLC, and is safe and feasible.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H and Jablons DM: Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 132:193–199. 2007. View Article : Google Scholar : PubMed/NCBI
3	Liu B, Liu L, Li Y, Wang H, Hu M, Qian K, Wang R and Zhi X: Survival after radiofrequency ablation for 100 cases of lung neoplasms. Zhongguo Fei Ai Za Zhi. 14:335–339. 2011.(In Chinese). PubMed/NCBI
4	Oshima F, Yamakado K, Akeboshi M, Takaki H, Nakatsuka A, Makita M and Takeda K: Lung radiofrequency ablation with and without bronchial occlusion: experimental study in porcine lungs. J Vasc Interv Radiol. 15:1451–1456. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zhao J, Wu Y, Wang Y, et al: Treatment of local late period NSCLC by RFA combined chemoradiotherapy. Cancer Res Prev Treat. 8:495–497. 2004.
6	Iguchi T, Hiraki T, Gobara H, Mimura H, Fujiwara H, Tajiri N, Sakurai J, Yasui K, Date H and Kanazawa S: Percutaneous radiofrequency ablation of lung tumors close to the heart or aorta: evaluation of safety and effectiveness. J Vasc Interv Radiol. 18:733–740. 2007. View Article : Google Scholar : PubMed/NCBI
7	Qian K, Zhang Y, Zhi XY, Liu BD, Su L, Li Y and Wang H: Study on the safety of radiofrequency ablation in patients with lung cancer above 70 years old. Chinese J Clinicians (Electronic Edition). 7:5332–5334. 2013.(In Chinese).
8	Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P and Pappagallo G: Impact of third- generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist. 14:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
9	Goldberg SN, Gazelle GS and Mueller PR: Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 174:323–331. 2000. View Article : Google Scholar : PubMed/NCBI
10	Liu B, Zhi X, Liu L, Hu M, Wang R, Xu Q, Zhang Y and Su L: Evaluation of three-dimensional reconstruction CT in percutaneous radiofrequency ablation (RFA) of the unresectable lung tumor with a clustered electrode. Zhongguo Fei Ai Za Zhi. 12:775–779. 2009.(In Chinese). PubMed/NCBI
11	Anderson EM, Lees WR and Gillams AR: Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol. 32:478–483. 2009. View Article : Google Scholar : PubMed/NCBI
12	Higaki F, Okumura Y, Sato S, Hiraki T, Gobara H, Mimura H, Akaki S, Tsuda T and Kanazawa S: Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med. 22:157–163. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Wang Y and Zhao J: Short-term and long-term effect of RFA on local late period NSCLC. Int Med Health Guidance News. 12:20–23. 2006.(In Chinese).
14	Mohamed Lotayef, Azza Taher, Hanna Attia, Azza Nasr, El Hossieny Hisham, Mohammed Mahmoud and Noha Essam: A clinic-epidemilogical study of cases of locally advanced non small cell lung cancer (NSCLC) that received radiotherapy at NCI Cairo in the period from 2001–2010. J Cancer Ther. 5:542–551. 2014. View Article : Google Scholar